Company / Total Assets
Arbutus Biopharma Corp Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$94.6M
FY2025
5-year range
$94.6M / $204.5M
FY2021-FY2025
Trend
-28.2%
vs FY2024
Sector context
#208 of 214
Health Care
What the data says
Among 214 Health Care companies, Arbutus Biopharma Corp is in the bottom 3% for total assets. Total Assets has declined for 4 consecutive years, from $204M in FY2021 to $95M in FY2025.
Based on SEC 10-K filings.
$95M in FY2025 with a 5-year CAGR of -7.1%.
Declined from $144M to $95M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -21.5%
- 5-Year CAGR
- -7.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 214This company $94.6M Sector average $7.5B
▼
-98.7% below sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's total assets has declined for 4 consecutive years.
- 5-year CAGR of -7.1%, indicating a declining trend.
- In FY2025, total assets decreased 28.2% year-over-year.
- Ranks #208 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $94.6M | -28.2% |
| FY2024 | $131.7M | -8.8% |
| FY2023 | $144.4M | -26.1% |
| FY2022 | $195.4M | -4.4% |
| FY2021 | $204.5M | +49.2% |
| FY2020 | $137.1M | +29.9% |
| FY2019 | $105.5M | -53.7% |
| FY2018 | $227.9M | -3.9% |
| FY2017 | $237.2M | -14.0% |
| FY2016 | $275.9M | -61.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026